Quantinno Capital Management LP Acquires 5,019 Shares of Axsome Therapeutics, Inc. $AXSM

Posted by Geri Gentry on Aug 12th, 2026

Quantinno Capital Management LP boosted its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 77.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,497 shares of the company’s stock after purchasing an additional 5,019 shares during the quarter. Quantinno Capital Management LP’s holdings in Axsome Therapeutics were worth $1,943,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Axsome Therapeutics by 4.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company’s stock valued at $2,557,000 after acquiring an additional 1,002 shares during the period. Jones Financial Companies Lllp grew its stake in shares of Axsome Therapeutics by 2,407.9% in the first quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company’s stock worth $889,000 after acquiring an additional 7,320 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Axsome Therapeutics by 38.7% during the first quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company’s stock worth $35,189,000 after acquiring an additional 84,151 shares during the period. Caxton Associates LLP bought a new position in Axsome Therapeutics during the first quarter worth $307,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Axsome Therapeutics by 29.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company’s stock valued at $8,735,000 after purchasing an additional 17,250 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Insider Buying and Selling at Axsome Therapeutics

In related news, Director Susan Mahony sold 300 shares of the firm’s stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $237.21, for a total transaction of $71,163.00. Following the completion of the sale, the director directly owned 1,129 shares of the company’s stock, valued at $267,810.09. This trade represents a 20.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Herriot Tabuteau sold 4,660 shares of Axsome Therapeutics stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $213.95, for a total value of $997,007.00. Following the completion of the transaction, the chief executive officer owned 7,229 shares of the company’s stock, valued at approximately $1,546,644.55. The trade was a 39.20% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 200,766 shares of company stock worth $46,685,646 over the last 90 days. Company insiders own 20.60% of the company’s stock.

Key Headlines Impacting Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

Positive Sentiment: Auvelity continues to drive growth. Second-quarter net product revenue increased 46% year over year, led primarily by Auvelity sales. Growth benefited from the product’s expanded use in Alzheimer’s disease agitation and a larger commercial sales force. Axsome’s Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues
Positive Sentiment: Pipeline ambitions support the long-term outlook. Management said it expects to file approximately one new drug application annually through 2030. AXS-12 is currently targeting a May 1, 2027 PDUFA date, providing a potential future catalyst. Axsome signals one NDA per year through 2030
Positive Sentiment: Needham raised its price target. Needham increased its target from $267 to $268 and maintained a Buy rating, implying substantial upside based on the cited reference price. Needham raises Axsome price target
Neutral Sentiment: Reported short-interest data appear unreliable. The update lists zero short interest both currently and in the prior period, along with a zero-day days-to-cover ratio, so it provides no meaningful signal about investor positioning.
Negative Sentiment: Quarterly results missed on both key measures. Axsome reported a loss of $0.99 per share versus the $0.89 consensus estimate and revenue of $218.38 million versus expectations of $221.11 million. The company remains unprofitable, with rising SG&A expenses offsetting much of its commercial progress. Axsome second-quarter earnings results
Negative Sentiment: Valuation and execution concerns remain. Analysts and investors are questioning whether management’s roughly $8 billion peak-sales target for Auvelity is achievable, particularly as commercialization costs rise and profitability remains elusive.

Axsome Therapeutics Price Performance

Shares of Axsome Therapeutics stock opened at $215.77 on Wednesday. The company has a current ratio of 1.39, a quick ratio of 1.32 and a debt-to-equity ratio of 2.27. The stock has a market capitalization of $11.10 billion, a price-to-earnings ratio of -57.54 and a beta of 0.65. Axsome Therapeutics, Inc. has a 1-year low of $103.40 and a 1-year high of $260.19. The firm’s 50-day moving average price is $236.64 and its two-hundred day moving average price is $204.60.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.10). Axsome Therapeutics had a negative net margin of 24.68% and a negative return on equity of 275.76%. The firm had revenue of $218.38 million during the quarter, compared to the consensus estimate of $221.11 million. On average, equities analysts predict that Axsome Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on AXSM. Zacks Research downgraded shares of Axsome Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, July 20th. UBS Group began coverage on shares of Axsome Therapeutics in a report on Tuesday. They set a “market perform” rating on the stock. Guggenheim increased their target price on shares of Axsome Therapeutics from $260.00 to $275.00 and gave the company a “buy” rating in a research note on Tuesday. Mizuho decreased their target price on Axsome Therapeutics from $310.00 to $306.00 and set an “outperform” rating on the stock in a research report on Friday, July 31st. Finally, Wells Fargo & Company lifted their target price on Axsome Therapeutics from $255.00 to $256.00 and gave the stock an “overweight” rating in a research report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $267.10.

Read Our Latest Analysis on Axsome Therapeutics

About Axsome Therapeutics

(Free Report)

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.